Chris Viehbacher appointed Sanofi-Aventis CEO

Share this article:
Chris Viehbacher
Chris Viehbacher
Sanofi-Aventis announced September 10 that Chris Viehbacher will succeed Gerard Le Fur as the company's CEO, effective December 1, 2008. 

The announcement came two days after Viehbacher resigned his postion on GlaxoSmithKline's board, with plans to leave the company entirely. Viehbacher will remain executive director and president at GSK until December 1.

Viehbacher, also a PhRMA board member, was a contender for the CEO position at GSK following the retirement of Jean-Pierre Garnier last May. Andrew Witty, currently the CEO at GSK, secured that postion.

According to a statement from the Sanofi board of directors, Le Fur will stay on at Sanofi after Viehbacher becomes CEO, and will "provide his competences to the general management of the group in the scientific domain." The financial conditions of Viehbacher's hiring will be posted online in the coming days, according to the Sanofi statement. 
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...